MX2010000716A - Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa. - Google Patents
Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.Info
- Publication number
- MX2010000716A MX2010000716A MX2010000716A MX2010000716A MX2010000716A MX 2010000716 A MX2010000716 A MX 2010000716A MX 2010000716 A MX2010000716 A MX 2010000716A MX 2010000716 A MX2010000716 A MX 2010000716A MX 2010000716 A MX2010000716 A MX 2010000716A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- bicyclic heteroaryl
- heteroaryl compounds
- alone
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describen compuestos inhibidores de cinasa de fosfatidilinositol (PI)-3, sus sales farmacéuticamente aceptables, y los pro-fármacos de los mismos; composiciones de los nuevos compuestos, ya sea solos o bien en combinación con cuando menos un agente terapéutico adicional, con un vehículo farmacéuticamente aceptable; y usos de los nuevos compuestos, ya sea solos o bien en combinación con cuando menos un agente terapéutico adicional, en la profilaxis o el tratamiento de las enfermedades proliferativas caracterizadas por una actividad anormal de los factores de crecimiento, las cinasas de proteína serina/treonina, y las cinasas de fosfolípido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07112688 | 2007-07-18 | ||
PCT/EP2008/059298 WO2009010530A1 (en) | 2007-07-18 | 2008-07-16 | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010000716A true MX2010000716A (es) | 2010-03-26 |
Family
ID=38800784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010000716A MX2010000716A (es) | 2007-07-18 | 2008-07-16 | Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa. |
Country Status (15)
Country | Link |
---|---|
US (1) | US8053574B2 (es) |
EP (1) | EP2178868A1 (es) |
JP (1) | JP2010533680A (es) |
KR (1) | KR20100049073A (es) |
CN (1) | CN101801966A (es) |
AR (1) | AR067562A1 (es) |
AU (1) | AU2008277628B2 (es) |
BR (1) | BRPI0813831A2 (es) |
CA (1) | CA2693232A1 (es) |
CL (1) | CL2008002097A1 (es) |
EA (1) | EA201000130A1 (es) |
MX (1) | MX2010000716A (es) |
PE (1) | PE20090492A1 (es) |
TW (1) | TW200908969A (es) |
WO (1) | WO2009010530A1 (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
CN103641829A (zh) | 2006-08-30 | 2014-03-19 | 塞尔佐姆有限公司 | 作为激酶抑制剂的三唑衍生物 |
AU2008282728B2 (en) | 2007-08-02 | 2012-04-19 | Amgen Inc. | Pl3 kinase modulators and methods of use |
KR20100086492A (ko) | 2007-11-27 | 2010-07-30 | 셀좀 리미티드 | Pi3k 억제제로서의 아미노 트리아졸 |
CA2710194C (en) * | 2007-12-19 | 2014-04-22 | Amgen Inc. | Inhibitors of p13 kinase |
JP2011518168A (ja) | 2008-04-16 | 2011-06-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | ホスファチジルイノシトール3−キナーゼの阻害薬 |
EP2444403A1 (en) | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
EP2307400B1 (en) | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitors of pi3 kinase |
WO2010010186A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010188A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
JP5792621B2 (ja) | 2008-09-26 | 2015-10-14 | オンコメッド ファーマシューティカルズ インコーポレイテッド | frizzled結合剤およびその使用 |
JP5551614B2 (ja) | 2008-12-24 | 2014-07-16 | 第一三共株式会社 | 環状アミン化合物 |
NZ593676A (en) | 2008-12-24 | 2012-06-29 | Daiichi Sankyo Co Ltd | Calcium-sensing receptor antagonists |
WO2010092015A1 (en) * | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
EP2408773A2 (en) | 2009-03-20 | 2012-01-25 | Amgen, Inc | Inhibitors of pi3 kinase |
WO2010125799A1 (ja) | 2009-04-27 | 2010-11-04 | 塩野義製薬株式会社 | Pi3k阻害活性を有するウレア誘導体 |
US8367830B2 (en) | 2009-05-20 | 2013-02-05 | Cellzome Ag | Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins |
WO2010141796A2 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
AU2010268058A1 (en) * | 2009-07-02 | 2012-01-19 | Novartis Ag | 2-carboxamide cycloamino ureas useful as PI3K inhibitors |
EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
EP2343295A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
JP6088425B2 (ja) * | 2010-06-01 | 2017-03-01 | アンジオン バイオメディカ コーポレーション | チトクロームp450阻害剤およびその使用 |
UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
PT2699575E (pt) | 2011-04-21 | 2015-07-29 | Bayer Ip Gmbh | Triazolopiridinas |
WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP2015502958A (ja) * | 2011-12-09 | 2015-01-29 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんの処置のための併用療法 |
UA112096C2 (uk) | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
EP2825540B1 (en) | 2012-03-14 | 2016-09-14 | Bayer Intellectual Property GmbH | Substituted imidazopyridazines |
SG11201408419QA (en) | 2012-07-10 | 2015-01-29 | Bayer Pharma AG | Method for preparing substituted triazolopyridines |
WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
EA035391B1 (ru) | 2012-11-08 | 2020-06-05 | Ризен Фармасьютикалз Са | Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы |
WO2014121196A1 (en) | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
CN105377848A (zh) | 2013-06-11 | 2016-03-02 | 拜耳制药股份公司 | 取代的三唑并吡啶的前体药物衍生物 |
WO2015039333A1 (en) * | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
AU2015217073B2 (en) | 2014-02-13 | 2019-08-22 | Incyte Holdings Corporation | Cyclopropylamines as LSD1 inhibitors |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
EP3105226B1 (en) | 2014-02-13 | 2019-09-04 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
US9598424B2 (en) | 2014-03-06 | 2017-03-21 | Takeda Pharmaceutical Company Limited | Heteroarylamide inhibitors of TBK1 |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
WO2017027678A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Salts of an lsd1 inhibitor |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
BR112018071585B1 (pt) | 2016-04-22 | 2024-01-02 | Incyte Corporation | Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas |
CN110248938A (zh) | 2016-11-23 | 2019-09-17 | 拜耳作物科学股份公司 | 用作农药的2-[3-(烷基磺酰基)-2h-吲唑-2-基]-3h-咪唑并[4,5-b]吡啶衍生物和类似化合物 |
WO2018098411A1 (en) * | 2016-11-28 | 2018-05-31 | Bristol-Myers Squibb Company | Gsk-3 inhibitors |
FI3692023T3 (fi) | 2017-10-02 | 2023-08-17 | 1St Biotherapeutics Inc | Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon |
IL303087B1 (en) | 2018-02-27 | 2024-08-01 | Incyte Corp | Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
CN113166153A (zh) | 2018-07-05 | 2021-07-23 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
AU2020224401A1 (en) | 2019-02-22 | 2021-10-14 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
EP3934702B1 (en) * | 2019-03-07 | 2024-05-08 | 1st Biotherapeutics, Inc. | [ 18f]-labeled benzothiazole derivative as pet radiotracer |
US10385046B1 (en) | 2019-03-19 | 2019-08-20 | 1ST Biotherapeutics, Inc. | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders |
CN111116580B (zh) * | 2019-12-27 | 2022-08-23 | 上海应用技术大学 | 一种尼麦角林的改进制备方法 |
WO2023180976A1 (en) * | 2022-03-25 | 2023-09-28 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods for using same |
CN118239953A (zh) * | 2022-12-23 | 2024-06-25 | 中国科学院合肥物质科学研究院 | 用于治疗PI3Kγ介导的疾病的化合物及其用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0261459A3 (de) * | 1986-09-09 | 1988-05-11 | Nihon Tokushu Noyaku Seizo K.K. | Neue N-Benzothiazolylamide |
NZ518637A (en) * | 1999-10-08 | 2004-12-24 | Gruenenthal Chemie | Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring |
CN1422262A (zh) * | 2000-02-07 | 2003-06-04 | 艾博特股份有限两合公司 | 2-苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用 |
EP1737459B1 (en) | 2004-03-19 | 2009-08-05 | Warner-Lambert Company LLC | Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents |
JP2008500284A (ja) * | 2004-05-12 | 2008-01-10 | ブリストル−マイヤーズ スクイブ カンパニー | 血栓症の治療に有用なp2y1レセプターのウレアアンタゴニスト |
US7636348B2 (en) * | 2004-06-30 | 2009-12-22 | Bettis Sonny R | Distributed IP architecture for telecommunications system with video mail |
US7524860B2 (en) | 2004-10-07 | 2009-04-28 | Pfizer Inc. | Antibacterial agents |
US7576090B2 (en) * | 2004-12-27 | 2009-08-18 | 4Sc Ag | Benzazole analogues and uses thereof |
-
2008
- 2008-07-16 JP JP2010516500A patent/JP2010533680A/ja not_active Withdrawn
- 2008-07-16 AR ARP080103052A patent/AR067562A1/es not_active Application Discontinuation
- 2008-07-16 CN CN200880107620A patent/CN101801966A/zh active Pending
- 2008-07-16 CA CA2693232A patent/CA2693232A1/en not_active Abandoned
- 2008-07-16 EA EA201000130A patent/EA201000130A1/ru unknown
- 2008-07-16 US US12/669,536 patent/US8053574B2/en not_active Expired - Fee Related
- 2008-07-16 AU AU2008277628A patent/AU2008277628B2/en not_active Expired - Fee Related
- 2008-07-16 WO PCT/EP2008/059298 patent/WO2009010530A1/en active Application Filing
- 2008-07-16 MX MX2010000716A patent/MX2010000716A/es not_active Application Discontinuation
- 2008-07-16 PE PE2008001205A patent/PE20090492A1/es not_active Application Discontinuation
- 2008-07-16 BR BRPI0813831-1A2A patent/BRPI0813831A2/pt not_active IP Right Cessation
- 2008-07-16 EP EP08775120A patent/EP2178868A1/en not_active Withdrawn
- 2008-07-16 KR KR1020107003426A patent/KR20100049073A/ko not_active Application Discontinuation
- 2008-07-17 TW TW097127181A patent/TW200908969A/zh unknown
- 2008-07-17 CL CL2008002097A patent/CL2008002097A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA201000130A1 (ru) | 2010-08-30 |
WO2009010530A1 (en) | 2009-01-22 |
KR20100049073A (ko) | 2010-05-11 |
AU2008277628B2 (en) | 2012-03-15 |
EP2178868A1 (en) | 2010-04-28 |
BRPI0813831A2 (pt) | 2015-01-06 |
AU2008277628A1 (en) | 2009-01-22 |
US20100197682A1 (en) | 2010-08-05 |
US8053574B2 (en) | 2011-11-08 |
TW200908969A (en) | 2009-03-01 |
CN101801966A (zh) | 2010-08-11 |
CL2008002097A1 (es) | 2009-02-20 |
CA2693232A1 (en) | 2009-01-22 |
AR067562A1 (es) | 2009-10-14 |
JP2010533680A (ja) | 2010-10-28 |
PE20090492A1 (es) | 2009-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010000716A (es) | Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa. | |
JO2660B1 (en) | Pi-3 inhibitors and methods of use | |
MX2008010397A (es) | Inhibidores de pi-3 quinasa y metodos para su uso. | |
MX2009008341A (es) | Inhibidores de cinasa de pi3 y metodos para su uso. | |
MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
MX2009011950A (es) | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
PH12015500666A1 (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
TN2014000068A1 (en) | Compounds and compositions as c-kit kinase inhibitors | |
TN2014000061A1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
ATE456565T1 (de) | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren | |
UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
TN2011000293A1 (en) | Protein kinase inhibitors | |
SG178591A1 (en) | Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | |
EP3722296A3 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
IL219643A0 (en) | Kinase inhibitors and methods of use thereof | |
CR20210364A (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
WO2018057808A8 (en) | Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
CY1114282T1 (el) | Παραγωγα πυριμιδινης που χρησιμοποιουνται ως αναστολεις της pi-3 κινασης | |
CU20080137A7 (es) | Derivados de pirimidina usados como inhibidores de pi-3 quinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |